From real-world events to psychosis: The emerging neuropharmacology of delusions

Schizophrenia Bulletin

Volumn 35, Issue 4, 2009, Pages 668-674

  Morrison, Paul D ^a   Murray, R M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Dopamine; Endocannabinoid; GABA; Glutamate; Psychosis; Schizophrenia

Indexed keywords

5 (4 BROMOPHENYL) 1 (2,4 DICHLOROPHENYL) 4 ETHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ADENOSINE; ANTIPARKINSON AGENT; CANNABINOID 1 RECEPTOR; DIPYRIDAMOLE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DRONABINOL; ENDOCANNABINOID; GLUTAMIC ACID; HALOPERIDOL; METHAMPHETAMINE; METHYLXANTHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT;

AFFECT; BASAL GANGLION; CENTRAL NERVOUS SYSTEM; COGNITION; CORPUS STRIATUM; DELUSION; DENDRITE; FUNCTIONAL ANATOMY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GABAERGIC SYSTEM; GLOBUS PALLIDUS; HUMAN; LEARNING; LIMBIC SYSTEM; LONG TERM DEPRESSION; MEDIUM SPINY NEURON; MENTAL DISEASE; MOTOR ACTIVITY; NEGATIVE FEEDBACK; NEOCORTEX; NERVE CELL; NERVE CELL PLASTICITY; NERVE FIBER; NEUROPHARMACOLOGY; OXYGEN BLOOD LEVEL; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; PSYCHOSIS; REVIEW; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; SYNAPSE; ARTICLE; PSYCHOLOGY; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA; CORPUS STRIATUM; DELUSIONS; DOPAMINE; HUMANS; LEARNING; NEUROPHARMACOLOGY; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SYNAPTIC TRANSMISSION;

EID: 68149158212     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbp049     Document Type: Review

References (66)

1. Kapur S, Mizrahi R, Li M. From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis. Schizophr Res. 2005;79:59-68.
2. Nieuwenhuys R, Voogd J, van Huijzen C. The Human Central Nervous System. Berlin, Heidelberg; New York: Springer-Verlag; 2008.
3. Haber SN, Calzavara R. The cortico-basal ganglia integrative network: the role of the thalamus. Brain Res Bull. 2009;78:69-74.
4. Rolls ETT, A. Neural networks and Brain Function. Oxford university press; 1997.
5. Graybiel AM. The basal ganglia and chunking of action repertoires. Neurobiol Learn Mem. 1998;70:119-136.
6. Houk JC, Bastianen C, Fansler D, et al. Action selection and refinement in subcortical loops through basal ganglia and cerebellum. Philos Trans R Soc Lond B Biol Sci. 2007;362:1573-1583.
7. Yin HH, Knowlton BJ. The role of the basal ganglia in habit formation. Nat Rev. 2006;7:464-476.
8. Redgrave P, Prescott TJ, Gurney K. The basal ganglia: a vertebrate solution to the selection problem? Neuroscience. 1999;89:1009-1023.
9. Graybiel AM. The basal ganglia: learning new tricks and loving it. Curr Opin Neurobiol. 2005;15:638-644.
10. Seger CA. The basal ganglia in human learning. Neuroscientist. 2006;12:285-290.
11. Pasupathy A, Miller EK. Different time courses of learning-related activity in the prefrontal cortex and striatum. Nature. 2005;433:873-876.
12. Seger CA, Cincotta CM. Dynamics of frontal, striatal, and hippocampal systems during rule learning. Cereb Cortex. 2006;16:1546-1555.
13. Wilson CJ, Kawaguchi Y. The origins of two-state spontaneous membrane potential fluctuations of neostriatal spiny neurons. J Neurosci. 1996;16:2397-2410.
14. Wickens JR. Synaptic plasticity in the basal ganglia. Behav Brain Res. 2009;199:119-128.
15. Karlsson P, Smith L, Farde L, Harnryd C, Sedvall G, Wiesel FA. Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology. 1995;121:309-316.
16. de Beaurepaire R, Labelle A, Naber D, Jones BD, Barnes TR. An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states. Psychopharmacology. 1995;121: 323-327.
17. Schultz W. Getting formal with dopamine and reward. Neuron. 2002;36:241-263.
18. Schultz W, Tremblay L, Hollerman JR. Changes in behavior-related neuronal activity in the striatum during learning. Trends Neurosci. 2003;26:321-328. (Pubitemid 36694320)
19. Calabresi P, Picconi B, Tozzi A, Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci. 2007;30:211-219.
20. Shen W, Flajolet M, Greengard P, Surmeier DJ. Dichoto-mous dopaminergic control of striatal synaptic plasticity. Science. 2008;321:848-851.
21. Gerdeman GL, Ronesi J, Lovinger DM. Postsynaptic endo-cannabinoid release is critical to long-term depression in the striatum. Nat Neuroscience. 2002;5:446-451.
22. Robbe D, Kopf M, Remaury A, Bockaert J, Manzoni OJ. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci U S A. 2002;99:8384-8388.
23. Ronesi J, Gerdeman GL, Lovinger DM. Disruption of endo-cannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport. J Neurosci. 2004;24:1673-1679.
24. Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature. 2007;445:643-647.
25. McKenna P. Schizophrenia and Related Syndromes. Routledge; 2007.
26. Abi-Dargham A, Rodenhiser J, Printz D, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A. 2000;97:8104-8109.
27. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci. 1999;2:358-363.
28. Kreitzer AC, Malenka RC. Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J Neurosci. 2005;25:10537-10545.
29. Yin HH, Lovinger DM. Frequency-specific and D2 receptor-mediated inhibition of glutamate release by retrograde endo-cannabinoid signaling. Proc Natl Acad Sci U S A. 2006;103: 8251-8256.
30. Pawlak V, Kerr JN. Dopamine receptor activation is required for corticostriatal spike-timing-dependent plasticity. J Neuro-sci. 2008;28:2435-2446.
31. D'Souza DC, Perry E, MacDougall L, et al. The psychotomi-metic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29:1558-1572.
32. D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9-tet-rahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005;57: 594-608.
33. Morrison PD, Zois V, McKeown DA, et al. The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning [published online ahead of print April 01, 2009]. Psychol Med. doi:10.1017/S0033291709005522.
34. Henquet C, Rosa A, Krabbendam L, et al. An experimental study of catechol-o-methyltransferase val(158)met moderation of delta-9- tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology. 2006;31:2748-2757.
35. Bhattacharyya S, Fusar-Poli P, Borgwardt S, et al. Modulation of mediotemporal and ventrostriatal function in humans by Delta9- tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry. 2009;66:442-451.
36. D'Souza DC, Braley G, Blaise R, et al. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroen-docrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology. 2008;198:587-603.
37. Chiang YC, Chen JC. The role of the cannabinoid type 1 receptor and down-stream cAMP/DARPP-32 signal in the nucleus accumbens of methamphetamine-sensitized rats. J Neurochem. 2007;103:2505-2517.
38. Pertwee RG. The diverse CB(1) and CB(2) receptor pharmacology of three plant cannabinoids: Delta(9)-tetrahydrocannabinol, cannabidiol and Delta(9)-tetrahydrocannabivarin. Br J Pharmacology. 2008;153:199-215.
39. Zuardi A, Crippa J, Hallak J, et al. Cannabidiol for the treatment of psychosis in Parkinson's disease [published online ahead of print November 21, 2008]. J Psychopharmacol. doi:10.1177/0269881108096519.
40. Akhondzadeh S, Shasavand E, Jamilian H, Shabestari O, Kamalipour A. Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. J Clin Pharm Ther. 2000;25:131-137.
41. Lucas PB, Pickar D, Kelsoe J, Rapaport M, Pato C, Hommer D. Effects of the acute administration of caffeine in patients with schizophrenia. Biol Psychiatry. 1990;28:35-40.
42. Zaslove MO, Russell RL, Ross E. Effect of caffeine intake on psychotic in-patients. Br J Psychiatry. 1991;159:565-567.
43. Chevaleyre V, Takahashi KA, Castillo PE. Endocannabi-noid-Mediated Synaptic Plasticity in the CNS. Annu Rev Neurosci. 2006;29:37-76.
44. Abe K, Niikura Y, Fujimoto T, Akaishi T, Misawa M. Involvement of dopamine D2 receptors in the induction of long-term potentiation in the basolateral amygdala-dentate gyrus pathway of anesthetized rats. Neuropharmacology. 2008;55:1419-1424.
45. Huang YC, Wang SJ, Chiou LC, Gean PW. Mediation of amphetamine-induced long-term depression of synaptic transmission by CB1 cannabinoid receptors in the rat amygdala. J Neurosci. 2003;23:10311-10320.
46. Kofalvi A, Rodrigues RJ, Ledent C, et al. Involvement of can-nabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci. 2005;25:2874-2884.
47. Matyas F, Yanovsky Y, Mackie K, Kelsch W, Misgeld U, FreundTF. Subcellularlocalizationoftype1cannabinoidrecep-tors in the rat basal ganglia. Neuroscience. 2006;137:337-361.
48. Uchigashima M, Narushima M, Fukaya M, Katona I, Kano M, Watanabe M. Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci. 2007;27:3663-3676.
49. Adermark L, Talani G, Lovinger DM. Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity. Eur J Neurosci. 2009;29:32-41.
50. Narushima M, Uchigashima M, Hashimoto K, Watanabe M, Kano M. Depolarization-induced suppression of inhibition mediated by endocannabinoids at synapses from fast-spiking interneurons to medium spiny neurons in the striatum. Eur J Neurosci. 2006;24:2246-2252.
51. Freiman I, Anton A, Monyer H, Urbanski MJ, Szabo B. Analysis of the effects of cannabinoids on identified synaptic connections in the caudate-putamen by paired recordings in transgenic mice. J Physiol. 2006;575:789-806.
52. Szabo B, Dorner L, Pfreundtner C, Norenberg W, Starke K. Inhibition of GABAergic inhibitory postsynaptic currents by can-nabinoidsin rat corpus striatum. Neuroscience. 1998;85:395-403.
53. Lewis DA, Gonzalez-Burgos G. Neuroplasticity of neocorti-cal circuits in schizophrenia. Neuropsychopharmacology. 2008;33:141-165.
54. Katona I, Sperlagh B, Sik A, et al. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neu-rosci. 1999;19:4544-4558.
55. Tsou K, Mackie K, Sanudo-Pena MC, Walker JM. Cannabi-noid CB1 receptors are localized primarily on cholecystoki-nin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience. 1999;93:969-975.
56. Bodor AL, Katona I, Nyiri G, et al. Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J Neurosci. 2005;25:6845-6856.
57. Eggan SM, Lewis DA. Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb Cortex.17:175-191.
58. Fukai T, Tanaka S. A simple neural network exhibiting selective activation of neuronal ensembles: from winner-take-all to winners-share-all. Neural Comput. 1997;9:77-97.
59. Wickens JR, Arbuthnott GW, Shindou T. Simulation of GABA function in the basal ganglia: computational models of GABAergic mechanisms in basal ganglia function. Prog Brain Res. 2007;160:313-329.
60. Hilario MR, Clouse E, HH Y, RM C. Endocannabinoid Signaling is Critical for Habit Formation. Front Integr Neurosci. 2007;1:6.
61. Shindou T, Arbuthnott GW, Wickens JR. Actions of adeno-sine A 2A receptors on synaptic connections of spiny projection neurons in the neostriatal inhibitory network. J Neurophysiol. 2008;99:1884-1889.
62. Corbille AG, Valjent E, Marsicano G, et al. Role of canna-binoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. J Neurosci. 2007; 27:6937-6947.
63. Thiemann G, van der Stelt M, Petrosino S, Molleman A, Di Marzo V, Hasenöhrl RU. The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arach-idonoylglycerol, in amphetamine-induced behavioural sensiti-zation. Behav Brain Res. 2008;187:289-296.
64. Centonze D, Rossi S, De Chiara V, et al. Chronic cocaine sensitizes striatal GABAergic synapses to the stimulation of cannabinoid CB1 receptors. Eur J Neurosci. 2007;25: 1631-1640.
65. Centonze D, Battista N, Rossi S, et al. A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal gabaergic transmission. Neuropsychopharmacology. 2004;29:1488-1497.
66. Jaspers K. General Psychopathology. Baltimore: The John Hopkins University Press; 1997.